Patterns of discontinuation of atypical antipsychotics in the province of Québec: A retrospective prescription claims database analysis

Clinical Therapeutics

Volumn 32, Issue SUPPL. 1, 2010, Pages

  Moisan, Jocelyne ^a,b   Grégoire, Jean Pierre ^a,b  

^a UNIVERSITÉ LAVAL   (Canada)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

adherence; atypical antipsychotics; discontinuation; persistence

Indexed keywords

CLOZAPINE; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; ARTICLE; CANADA; DRUG UTILIZATION; FEMALE; HEALTH BEHAVIOR; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRESCRIPTION; RETROSPECTIVE STUDY; RISK ASSESSMENT;

ADULT; AGE DISTRIBUTION; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLOZAPINE; COHORT STUDIES; DATABASES, FACTUAL; DIBENZOTHIAZEPINES; DRUG PRESCRIPTIONS; DRUG THERAPY, COMBINATION; DRUG UTILIZATION; DRUG UTILIZATION REVIEW; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MENTAL DISORDERS; MIDDLE AGED; PATIENT COMPLIANCE; QUEBEC; REGISTRIES; RETROSPECTIVE STUDIES; RISPERIDONE; SEX DISTRIBUTION; YOUNG ADULT;

EID: 75349087414     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2010.01.003     Document Type: Article

References (11)

1. Glick I.D., Murray S.R., Vasudevan P., et al. Treatment with atypical antipsychotics: New indications and new populations. J Psychiatr Res. 35 (2001) 187-191
2. Tran P.V., Hamilton S.H., Kuntz A.J., et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 17 (1997) 407-418
3. Lieberman J.A., Stroup T.S., McEvoy J.P., et al., Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 353 (2005) 1209-1223
4. Cooper D., Moisan J., Gaudet M., et al. Ambulatory use of olanzapine and risperidone: A population-based study on persistence and the use of concomitant therapy in the treatment of schizophrenia. CanJ Psychiatry 50 (2005) 901-908
5. Mullins C.D., Obeidat N.A., Cuffel B.J., et al. Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia. Schizophr Res. 98 (2008) 8-15
6. Tamblyn R., Lavoie G., Petrella L., and Monette J. The use of prescription claims databases in pharmacoepidemiological research: The accuracy and comprehensiveness of the prescription claims database in Québec. J Clin Epidemiol 48 (1995) 999-1009
7. Rothman K.J., Greenland S., and Lash T.L. Modern Epidemiology. 3rd ed. (2008), Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia, Pa
8. Bourgault C., Rainville B., and Suissa S. Antihypertensive drug therapy in Saskatchewan: Patterns of use and determinants in hypertension. Arch Intern Med. 161 (2001) 1873-1879
9. Bourgault C., Sénécal M., Brisson M., et al. Persistence and discontinuation patterns of antihypertensive therapy among newly treated patients: A population-based study. J Hum Hypertens 19 (2005) 607-613
10. Brookhart M.A., Patrick A.R., Schneeweiss S., et al. Physician follow-up and provider continuity are associated with long-term medication adherence: A study of the dynamics of statin use. Arch Intern Med. 167 (2007) 847-852
11. Law M.R., Soumerai S.B., Ross-Degnan D., and Adams A.S. A longitudinal study of medication nonadherence and hospitalization risk in schizophrenia. J Clin Psychiatry 69 (2008) 47-53